Clinuvel Pharmaceuticals

Historical price data

Clinuvel Pharmaceuticals is a mission-driven company focused on developing and commercializing treatments for severe, often rare, disorders of the skin and brain with no alternative therapies. Its core achievement is the global approval and commercialization of SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP), establishing it as a leader in photomedicine. The company's strategy leverages this foundational melanocortin platform to expand into adjacent indications like vitiligo and stroke, while simultaneously commercializing a luxury PhotoCosmetics division to diversify revenue and fund R&D.

Proprietary platform based on melanocortin receptor biology, utilizing synthetic agonists like afamelanotide to activate MC1R for systemic photoprotection, DNA repair enhancement, and anti-inflammatory effects, and CNS receptors for neuroprotection.

Holds a monopoly in EPP with SCENESSE® protected by orphan drug exclusivity. In vitiligo, faces competition from approved (Incyte's Opzelura) and developing JAK inhibitors, but offers a mechanistically distinct, physiology-based approach. In stroke, enters a high-risk, high-reward arena with a differentiated neuroprotective mechanism.